Dr. Reddy's receives EC marketing authorization for AVT03 (denosumab)



Dr Reddys Laboratories announced that the European Commission (EC) has granted marketing authorization for AVT03, a biosimilar of Prolia (denosumab) and Xgeva (denosumab).



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *